Trill Impact
Bita Sehat, PhD, MBA has a rich background in the life sciences industry, with experience in investment management, board memberships, and consulting services. Bita is currently a Senior Investment Director at Trill Impact and a Startup Mentor at EIT Health. Bita has also served on the boards of Minervax ApS and Gesynta Pharma AB, both pharmaceutical companies developing novel treatments. Additionally, Bita has experience in business intelligence and asset valuation at Foster Rosenblatt. Bita holds a PhD in Molecular Oncology from Karolinska Institutet and an MBA from Concordia University.
Trill Impact
Trill Impact is a pioneering Impact House with around EUR 1.2 billion in assets under management across its investment strategies and with a team of around 50 experienced professionals based in the Nordics, Germany, Luxembourg and USA. Trill Impact aims to become a force for positive change through impact private investments, delivering Real Returns and Lasting Impact for the benefit of investors, businesses and society at large - encouraging others to follow. _______________________________________________________________________________ References to “we”, “us” and “our” in these Terms and Conditions shall, where appropriate, include Trill Impact AB and other members of our group of companies and third parties connected to us. Depending on the context, Trill Impact may also refer to private funds where we or our subsidiaries serve as investment advisors or general partners.